Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Symbionts exploit complex signaling to educate the immune system.

Erturk-Hasdemir D, Oh SF, Okan NA, Stefanetti G, Gazzaniga FS, Seeberger PH, Plevy SE, Kasper DL.

Proc Natl Acad Sci U S A. 2019 Dec 6. pii: 201915978. doi: 10.1073/pnas.1915978116. [Epub ahead of print]

PMID:
31811024
2.

Whole-Virome Analysis Sheds Light on Viral Dark Matter in Inflammatory Bowel Disease.

Clooney AG, Sutton TDS, Shkoporov AN, Holohan RK, Daly KM, O'Regan O, Ryan FJ, Draper LA, Plevy SE, Ross RP, Hill C.

Cell Host Microbe. 2019 Dec 11;26(6):764-778.e5. doi: 10.1016/j.chom.2019.10.009. Epub 2019 Nov 19.

PMID:
31757768
3.

The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis.

Manthey CL, Moore BA, Chen Y, Loza MJ, Yao X, Liu H, Belkowski SM, Raymond-Parks H, Dunford PJ, Leon F, Towne JE, Plevy SE.

PLoS One. 2019 Nov 11;14(11):e0223918. doi: 10.1371/journal.pone.0223918. eCollection 2019.

4.

Phosphoinositide 3-Kinase P110δ-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation.

Oka A, Mishima Y, Liu B, Herzog JW, Steinbach EC, Kobayashi T, Plevy SE, Sartor RB.

Cells. 2019 Sep 21;8(10). pii: E1121. doi: 10.3390/cells8101121.

5.

Dietary iron variably modulates assembly of the intestinal microbiota in colitis-resistant and colitis-susceptible mice.

Ellermann M, Gharaibeh RZ, Maharshak N, Peréz-Chanona E, Jobin C, Carroll IM, Arthur JC, Plevy SE, Fodor AA, Brouwer CR, Sartor RB.

Gut Microbes. 2020;11(1):32-50. doi: 10.1080/19490976.2019.1599794. Epub 2019 Jun 10.

6.

Challenges in IBD Research: Environmental Triggers.

Ho SM, Lewis JD, Mayer EA, Plevy SE, Chuang E, Rappaport SM, Croitoru K, Korzenik JR, Krischer J, Hyams JS, Judson R, Kellis M, Jerrett M, Miller GW, Grant ML, Shtraizent N, Honig G, Hurtado-Lorenzo A, Wu GD.

Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S13-S23. doi: 10.1093/ibd/izz076. Erratum in: Inflamm Bowel Dis. 2019 Nov 14;25(12):e171.

PMID:
31095702
7.

Low-Dose Interleukin-2 Ameliorates Colitis in a Preclinical Humanized Mouse Model.

Goettel JA, Kotlarz D, Emani R, Canavan JB, Konnikova L, Illig D, Frei SM, Field M, Kowalik M, Peng K, Gringauz J, Mitsialis V, Wall SM, Tsou A, Griffith AE, Huang Y, Friedman JR, Towne JE, Plevy SE, O'Hara Hall A, Snapper SB.

Cell Mol Gastroenterol Hepatol. 2019;8(2):193-195. doi: 10.1016/j.jcmgh.2019.05.001. Epub 2019 May 9. No abstract available.

8.

Publisher Correction: Get the IL-17F outta here!

O'Hara Hall A, Towne JE, Plevy SE.

Nat Immunol. 2019 Mar;20(3):374. doi: 10.1038/s41590-019-0332-2.

PMID:
30705416
9.

Get the IL-17F outta here!

Hall AO, Towne JE, Plevy SE.

Nat Immunol. 2018 Jul;19(7):648-650. doi: 10.1038/s41590-018-0141-z. No abstract available. Erratum in: Nat Immunol. 2019 Mar;20(3):374.

PMID:
29915294
10.

Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.

Chen L, Wilson JE, Koenigsknecht MJ, Chou WC, Montgomery SA, Truax AD, Brickey WJ, Packey CD, Maharshak N, Matsushima GK, Plevy SE, Young VB, Sartor RB, Ting JP.

Nat Immunol. 2017 Oct 18;18(11):1270. doi: 10.1038/ni1117-1270b.

PMID:
29044233
11.

Erratum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.

Chen L, Wilson JE, Koenigsknecht MJ, Chou WC, Montgomery SA, Truax AD, Brickey WJ, Packey CD, Maharshak N, Matsushima GK, Plevy SE, Young VB, Sartor RB, Ting JP.

Nat Immunol. 2017 Jul 19;18(8):951. doi: 10.1038/ni0817-951e. No abstract available.

PMID:
28722719
12.

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788d. No abstract available.

PMID:
28586341
13.

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

14.

NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth.

Chen L, Wilson JE, Koenigsknecht MJ, Chou WC, Montgomery SA, Truax AD, Brickey WJ, Packey CD, Maharshak N, Matsushima GK, Plevy SE, Young VB, Sartor RB, Ting JP.

Nat Immunol. 2017 May;18(5):541-551. doi: 10.1038/ni.3690. Epub 2017 Mar 13. Erratum in: Nat Immunol. 2017 Jul 19;18(8):951. Erratum in: Nat Immunol. 2017 Oct 18;18(11):1270.

15.

Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE.

World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):213-22. doi: 10.4292/wjgpt.v6.i4.213.

16.

Escherichia coli heme oxygenase modulates host innate immune responses.

Maharshak N, Ryu HS, Fan TJ, Onyiah JC, Schulz S, Otterbein SL, Wong R, Hansen JJ, Otterbein LE, Carroll IM, Plevy SE.

Microbiol Immunol. 2015 Aug;59(8):452-65. doi: 10.1111/1348-0421.12282.

17.

Infliximab Re-treatment in Inflammatory Bowel Disease: A Single-Center Routine Clinical Experience.

Hughes JT, Herfarth HH, Isaacs KL, Plevy SE, Sartor RB, Sheikh SZ, Hansen JJ, Long MD.

Clin Gastroenterol Hepatol. 2015 Sep;13(9):1704-5. doi: 10.1016/j.cgh.2014.05.007. Epub 2014 May 14. No abstract available.

PMID:
24835819
18.

Toward an understanding of the gene-specific and global logic of inducible gene transcription.

Smale ST, Plevy SE, Weinmann AS, Zhou L, Ramirez-Carrozzi VR, Pope SD, Bhatt DM, Tong AJ.

Cold Spring Harb Symp Quant Biol. 2013;78:61-8. doi: 10.1101/sqb.2013.78.020313. Epub 2014 Apr 19.

PMID:
24747344
19.

Heme oxygenase-1 and carbon monoxide regulate intestinal homeostasis and mucosal immune responses to the enteric microbiota.

Onyiah JC, Sheikh SZ, Maharshak N, Otterbein LE, Plevy SE.

Gut Microbes. 2014 Mar-Apr;5(2):220-4. doi: 10.4161/gmic.27290. Epub 2013 Dec 20. Review.

20.

Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitis.

Steinbach EC, Kobayashi T, Russo SM, Sheikh SZ, Gipson GR, Kennedy ST, Uno JK, Mishima Y, Borst LB, Liu B, Herfarth H, Ting JP, Sartor RB, Plevy SE.

J Immunol. 2014 Apr 15;192(8):3958-68. doi: 10.4049/jimmunol.1301533. Epub 2014 Mar 14.

21.

NFIL3-deficient mice develop microbiota-dependent, IL-12/23-driven spontaneous colitis.

Kobayashi T, Steinbach EC, Russo SM, Matsuoka K, Nochi T, Maharshak N, Borst LB, Hostager B, Garcia-Martinez JV, Rothman PB, Kashiwada M, Sheikh SZ, Murray PJ, Plevy SE.

J Immunol. 2014 Feb 15;192(4):1918-27. doi: 10.4049/jimmunol.1301819. Epub 2014 Jan 17.

22.

Pharmacologic IKK/NF-κB inhibition causes antigen presenting cells to undergo TNFα dependent ROS-mediated programmed cell death.

Tilstra JS, Gaddy DF, Zhao J, Davé SH, Niedernhofer LJ, Plevy SE, Robbins PD.

Sci Rep. 2014 Jan 10;4:3631. doi: 10.1038/srep03631.

23.

Chloride channel ClC-2 is a key factor in the development of DSS-induced murine colitis.

Nighot P, Young K, Nighot M, Rawat M, Sung EJ, Maharshak N, Plevy SE, Ma T, Blikslager A.

Inflamm Bowel Dis. 2013 Dec;19(13):2867-77. doi: 10.1097/MIB.0b013e3182a82ae9.

24.

The role of macrophages and dendritic cells in the initiation of inflammation in IBD.

Steinbach EC, Plevy SE.

Inflamm Bowel Dis. 2014 Jan;20(1):166-75. doi: 10.1097/MIB.0b013e3182a69dca. Review.

25.

Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice.

Maseda D, Candando KM, Smith SH, Kalampokis I, Weaver CT, Plevy SE, Poe JC, Tedder TF.

J Immunol. 2013 Sep 1;191(5):2780-2795. doi: 10.4049/jimmunol.1300649. Epub 2013 Aug 5.

26.

Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda.

Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV Jr, Kappelman MD, Lewis JD, Parkos CA, Sartor RB; Challenges Workgroup.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):677-82. doi: 10.1097/MIB.0b013e31828134b3. No abstract available.

27.

Early life stress triggers persistent colonic barrier dysfunction and exacerbates colitis in adult IL-10-/- mice.

Lennon EM, Maharshak N, Elloumi H, Borst L, Plevy SE, Moeser AJ.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):712-9. doi: 10.1097/MIB.0b013e3182802a4e.

28.

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.

Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB.

Curr Med Res Opin. 2013 May;29(5):483-93. doi: 10.1185/03007995.2013.779575. Epub 2013 Mar 14.

PMID:
23438483
29.

NOD2 and pouch complications in UC patients: old-world clinical dogmas give way to biological definitions.

Dotan I, Plevy SE.

Gut. 2013 Oct;62(10):1390-1. doi: 10.1136/gutjnl-2012-303188. Epub 2013 Jan 3. No abstract available.

PMID:
23292664
30.

Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease.

Shinzaki S, Kuroki E, Iijima H, Tatsunaka N, Ishii M, Fujii H, Kamada Y, Kobayashi T, Shibukawa N, Inoue T, Tsujii M, Takeishi S, Mizushima T, Ogata A, Naka T, Plevy SE, Takehara T, Miyoshi E.

Inflamm Bowel Dis. 2013 Feb;19(2):321-31. doi: 10.1097/MIB.0b013e318280eade.

PMID:
23287897
31.

Carbon monoxide and heme oxygenase-1 prevent intestinal inflammation in mice by promoting bacterial clearance.

Onyiah JC, Sheikh SZ, Maharshak N, Steinbach EC, Russo SM, Kobayashi T, Mackey LC, Hansen JJ, Moeser AJ, Rawls JF, Borst LB, Otterbein LE, Plevy SE.

Gastroenterology. 2013 Apr;144(4):789-98. doi: 10.1053/j.gastro.2012.12.025. Epub 2012 Dec 22.

32.

In vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery.

Liu D, Kobayashi T, Russo S, Li F, Plevy SE, Gambling TM, Carson JL, Mumper RJ.

AAPS J. 2013 Jan;15(1):288-98. doi: 10.1208/s12248-012-9441-7. Epub 2012 Nov 30.

33.

IL-10 regulates Il12b expression via histone deacetylation: implications for intestinal macrophage homeostasis.

Kobayashi T, Matsuoka K, Sheikh SZ, Russo SM, Mishima Y, Collins C, deZoeten EF, Karp CL, Ting JP, Sartor RB, Plevy SE.

J Immunol. 2012 Aug 15;189(4):1792-9. doi: 10.4049/jimmunol.1200042. Epub 2012 Jul 11.

34.

Novel role for surfactant protein A in gastrointestinal graft-versus-host disease.

Gowdy KM, Cardona DM, Nugent JL, Giamberardino C, Thomas JM, Mukherjee S, Martinu T, Foster WM, Plevy SE, Pastva AM, Wright JR, Palmer SM.

J Immunol. 2012 May 15;188(10):4897-905. doi: 10.4049/jimmunol.1103558. Epub 2012 Apr 16. Erratum in: J Immunol. 2013 Feb 1;190(3):1382. Mukherjee, Sambudho [corrected to Mukherjee, Sambuddho].

35.

A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis.

Elloumi HZ, Maharshak N, Rao KN, Kobayashi T, Ryu HS, Mühlbauer M, Li F, Jobin C, Plevy SE.

PLoS One. 2012;7(3):e34172. doi: 10.1371/journal.pone.0034172. Epub 2012 Mar 27.

36.

Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.

Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, Ohkawara T, Nezu R, Nakajima S, Kobayashi T, Plevy SE, Takehara T, Naka T.

Inflamm Bowel Dis. 2012 Nov;18(11):2169-79. doi: 10.1002/ibd.22936. Epub 2012 Feb 28.

PMID:
22374925
37.

A Crohn's disease patient who does not respond to infliximab: what is next?

Maharshak N, Plevy SE.

Clin Gastroenterol Hepatol. 2011 Dec;9(12):1033-8. doi: 10.1016/j.cgh.2011.05.027. Epub 2011 Jun 6. No abstract available.

PMID:
21699811
38.

Future therapeutic approaches for inflammatory bowel diseases.

Plevy SE, Targan SR.

Gastroenterology. 2011 May;140(6):1838-46. doi: 10.1053/j.gastro.2011.02.014. Review.

39.

An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis.

Sheikh SZ, Hegazi RA, Kobayashi T, Onyiah JC, Russo SM, Matsuoka K, Sepulveda AR, Li F, Otterbein LE, Plevy SE.

J Immunol. 2011 May 1;186(9):5506-13. doi: 10.4049/jimmunol.1002433. Epub 2011 Mar 28.

40.

NFIL3 is a regulator of IL-12 p40 in macrophages and mucosal immunity.

Kobayashi T, Matsuoka K, Sheikh SZ, Elloumi HZ, Kamada N, Hisamatsu T, Hansen JJ, Doty KR, Pope SD, Smale ST, Hibi T, Rothman PB, Kashiwada M, Plevy SE.

J Immunol. 2011 Apr 15;186(8):4649-55. doi: 10.4049/jimmunol.1003888. Epub 2011 Mar 7.

41.

Characterization of an interferon-stimulated response element (ISRE) in the Il23a promoter.

Sheikh SZ, Kobayashi T, Matsuoka K, Onyiah JC, Plevy SE.

J Biol Chem. 2011 Jan 14;286(2):1174-80. doi: 10.1074/jbc.M110.147884. Epub 2010 Nov 21.

42.

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P.

Inflamm Bowel Dis. 2011 Jan;17(1):141-51. doi: 10.1002/ibd.21328.

PMID:
20848500
43.

The role of the macrophage in sentinel responses in intestinal immunity.

Sheikh SZ, Plevy SE.

Curr Opin Gastroenterol. 2010 Nov;26(6):578-82. doi: 10.1097/MOG.0b013e32833d4b71. Review.

44.

Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ.

Uno JK, Rao KN, Matsuoka K, Sheikh SZ, Kobayashi T, Li F, Steinbach EC, Sepulveda AR, Vanhaesebroeck B, Sartor RB, Plevy SE.

Gastroenterology. 2010 Nov;139(5):1642-53, 1653.e1-6. doi: 10.1053/j.gastro.2010.07.008. Epub 2010 Jul 14.

45.

Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis.

Sheikh SZ, Matsuoka K, Kobayashi T, Li F, Rubinas T, Plevy SE.

J Immunol. 2010 Apr 15;184(8):4069-73. doi: 10.4049/jimmunol.0903600. Epub 2010 Mar 12.

46.

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ.

Inflamm Bowel Dis. 2010 Apr;16(4):620-9. doi: 10.1002/ibd.21084.

PMID:
19714757
47.

Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.

Davé SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE.

J Leukoc Biol. 2009 Sep;86(3):633-43. doi: 10.1189/jlb.1008662. Epub 2009 May 19.

48.

Poorly responsive ulcerative colitis in the hospital.

Long MD, Plevy SE.

Clin Gastroenterol Hepatol. 2009 Jun;7(6):635-40. doi: 10.1016/j.cgh.2009.03.012. Epub 2009 Mar 21. Review. No abstract available.

49.

Infliximab prevents Crohn's disease recurrence after ileal resection.

Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE.

Gastroenterology. 2009 Feb;136(2):441-50.e1; quiz 716. doi: 10.1053/j.gastro.2008.10.051. Epub 2008 Oct 31.

PMID:
19109962
50.

Farm animals and inflammatory bowel disease: old MacDonald had poor hygiene.

Levy LC, Plevy SE.

Gastroenterology. 2008 Mar;134(3):886-7; discussion 887-8. doi: 10.1053/j.gastro.2008.01.047. No abstract available.

PMID:
18325401

Supplemental Content

Loading ...
Support Center